肝癌肿瘤浸润淋巴细胞的研究与应用  

Study and clinical application of tumor-infiltratinglymphocytes isolated from hepatocarcinoma

作　　者：王一[1] 陈汉[1] 吴孟超[1] 宝建中[1] 丛文铭[1] 王皓[1] 张秀忠[1] 

机构地区：[1]第二军医大学长海医院东方肝胆外科研究所,第二军医大学病理解剖学教研室

出　　处：《中华外科杂志》1995年第1期29-31,T001,共4页Chinese Journal of Surgery

摘　　要：作者研究了肝癌患者肿瘤浸润淋巴细胞（ＴＩＬ）的体外分离、扩增培养和临床治疗，其目的是寻求癌症术后综合治疗更为有效的方法。结果表明，１２例用于ＴＩＬ培养的肿瘤组织重量平均４．８ｇ，细胞数５．８×１０￣７，培养时间３１．８天，最大扩增倍数１０００倍。ＬＡＫ上清液能显著促进ＴＩＬ的扩增培养。本组对１０例患者进行了ＴＩＬ的临床治疗，采用了经肝动脉的输注途径，回输细胞量为４×１０￣８～１．１×１０￣（１０）肝癌ＴＩＬ还显示对靶细胞有明显杀伤活性。Abstract Tumor-infiltrating lymphocytes isolated fromfreshly resected tumors of 12 patients with hepatocarci-noma were propagated in vitro and infused to patients.The average weight of tumor for culture of TIL was4.8g,number of cells 5.8 × 10￣7,time for in vitro ex-pansion was 31.8 days,The maximal expansionachieved 1000 fold,with a mean amplification rate of198.5 fold.LAK cell culture supernatant stimulatedTIL growth.10 of 12 patients received clinical treat-ment,the number of cells infused reached 4 × 10￣8～1.1×10￣(10).TIL was infused by hepatic artery。TIL isolat-ed from hepatocarcinoma demonstrated cvtotoxic activi-ty to tumor targets.

关 键 词：肝肿瘤 免疫疗法 癌 淋巴细胞 

分 类 号：R735.705[医药卫生—肿瘤]